-
1.发明授权Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent 有权单克隆抗体Sc104及其与唾液酸四糖基碳水化合物特异性结合的衍生物作为潜在的抗肿瘤治疗剂公开(公告)号：US07915387B2
公开(公告)日：2011-03-29
申请号：US11596501
申请日：2005-05-11
IPC分类号： C07K16/00
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/75
摘要： The present invention provides an isolated specific binding member capable of binding a sialyltetraosly carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.
摘要翻译： 本发明提供了能够结合唾液酸四糖的直接诱导细胞死亡而不需要免疫效应细胞的分离的特异性结合成员。 这样的结合成员可以是抗体或其一部分。 还提供了这样的结合成员在药物中的用途以及编码这种结合成员的核酸。
-
2.发明申请Monoclonal Antibody Sc104 and Derivative Thereof Specifically Binding to a Sialyltetraosyl Carbohydrate as a Potential Anti-Tumor Therapeutic Agent 有权单克隆抗体Sc104及其衍生物具体结合唾液酸四糖基碳水化合物作为潜在的抗肿瘤治疗剂公开(公告)号：US20080118509A1
公开(公告)日：2008-05-22
申请号：US11596501
申请日：2005-05-11
IPC分类号： A61K39/395 , C07K16/18 , A61K31/35 , A61K31/335 , A61K31/505 , A61K33/24 , A61P43/00
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/75
摘要： The present invention provides an isolated specific binding member capable of binding a sialyltetraosly carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.
摘要翻译： 本发明提供了能够结合唾液酸四糖的直接诱导细胞死亡而不需要免疫效应细胞的分离的特异性结合成员。 这样的结合成员可以是抗体或其一部分。 还提供了这样的结合成员在药物中的用途以及编码这种结合成员的核酸。
-
3.发明授权Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent 有权单克隆抗体SC104及其与唾液酸四糖基碳水化合物特异性结合的衍生物作为潜在的抗肿瘤治疗剂公开(公告)号：US08343490B2
公开(公告)日：2013-01-01
申请号：US13020387
申请日：2011-02-03
IPC分类号： A61K39/395
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/75
摘要： The present invention provides an isolated specific binding member capable of binding a sialyltetraosyl carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.
摘要翻译： 本发明提供了能够结合唾液酸四糖基碳水化合物并直接诱导细胞死亡而不需要免疫效应细胞的分离的特异性结合成员。 这样的结合成员可以是抗体或其一部分。 还提供了这样的结合成员在药物中的用途以及编码这种结合成员的核酸。
-
4.发明申请Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses 有权能够结合CD64的多肽包含一个或多个异源T细胞表位及其用途公开(公告)号：US20110165180A1
公开(公告)日：2011-07-07
申请号：US12805752
申请日：2010-08-18
IPC分类号： A61K39/395 , C07K19/00 , A61P35/00 , A61P37/04
CPC分类号： C07K16/4266 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K16/00 , C07K2317/52 , C07K2317/74 , Y10S530/806
摘要： The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment.
摘要翻译： 本发明涉及多肽的用途，其包括i）包含结合CD64的人Fc部分的第一部分，和ii）包含刺激细胞毒性T细胞应答的一个或多个异源T细胞表位的第二部分。 多肽可以是可以用于刺激需要这种治疗的患者中针对病原体和肿瘤细胞的细胞毒性T细胞应答的抗体。
-
5.发明授权Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses 有权能够结合CD64的多肽包含一个或多个异源T细胞表位及其用途公开(公告)号：US08187600B2
公开(公告)日：2012-05-29
申请号：US12805752
申请日：2010-08-18
IPC分类号： A61K39/395
CPC分类号： C07K16/4266 , A61K39/00 , A61K2039/505 , A61K2039/53 , C07K16/00 , C07K2317/52 , C07K2317/74 , Y10S530/806
摘要： The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody that may be used to stimulate a cytotoxic T cell response against pathogens and tumor cells in patients in need of such treatment.
摘要翻译： 本发明涉及多肽的用途，其包括i）包含结合CD64的人Fc部分的第一部分，和ii）包含刺激细胞毒性T细胞应答的一个或多个异源T细胞表位的第二部分。 多肽可以是可以用于刺激需要这种治疗的患者中针对病原体和肿瘤细胞的细胞毒性T细胞应答的抗体。
-
6.发明申请Monoclonal Antibody SC104 and Derivative Thereof Specifically Binding to a Sialyltetraosyl Carbohydrate as a Potential Anti-Tumor Therapeutic Agent 有权单克隆抗体SC104及其衍生物具体结合唾液酸四糖基碳水化合物作为潜在的抗肿瘤治疗剂公开(公告)号：US20110212113A1
公开(公告)日：2011-09-01
申请号：US13020387
申请日：2011-02-03
IPC分类号： A61K39/395 , C07K16/18 , A61P35/00
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/75
摘要： The present invention provides an isolated specific binding member capable of binding a sialyltetraosyl carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.
摘要翻译： 本发明提供了能够结合唾液酸四糖基碳水化合物并直接诱导细胞死亡而不需要免疫效应细胞的分离的特异性结合成员。 这样的结合成员可以是抗体或其一部分。 还提供了这样的结合成员在药物中的用途以及编码这种结合成员的核酸。
-
7.发明申请BINDING MEMBER WHICH BINDS TO BOTH LEWIS-Y AND LEWIS-B HAPTENS, AND ITS USE FOR TREATING CANCER 有权绑定会员，其中包含LEWIS-Y和LEWIS-B HAPTENS，并且它用于治疗癌症公开(公告)号：US20090281285A1
公开(公告)日：2009-11-12
申请号：US12505313
申请日：2009-07-17
IPC分类号： C07K16/00
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K2317/73 , A61K2300/00
摘要： The invention relates to the use of a binding member which binds to Lewisy and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewisy and Lewisb haptens and cancer cells and induces cells death.
摘要翻译： 本发明涉及结合Lewisy和Lewisb半抗原的结合成分用于治疗肿瘤和白血病的用途。 结合成员可以是结合路易斯和路易斯半胱氨酸和癌细胞并诱导细胞死亡的抗体。
-
8.发明授权Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer 有权与Lewisy和Lewisb半抗原结合的结合成员及其用于治疗癌症的用途公开(公告)号：US07267821B2
公开(公告)日：2007-09-11
申请号：US10476233
申请日：2002-05-10
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K2317/73 , A61K2300/00
摘要： The invention relates to the use of a binding member which binds to Lewisy and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewisy and Lewisb haptens and cancer cells and induces cells death.
摘要翻译： 本发明涉及在治疗肿瘤和白血病中结合路易斯半胱氨酸和半抗原的结合成员的用途。 结合成员可以是结合路易斯和路易斯半抗原和癌细胞并诱导细胞死亡的抗体。
-
公开(公告)号：US6042827A
公开(公告)日：2000-03-28
申请号：US278693
申请日：1994-07-21
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/30 , C07K16/42 , C12N5/10 , C12N5/20 , C12P21/08 , C12R1/91
CPC分类号： C07K16/3046 , C07K16/4266 , A61K2039/505 , A61K38/00 , C07K2317/76 , Y10S530/809
摘要： Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions thereof to primary antibodies which bind selectively to an antigenic determinant of gp72 are provided to mediate the humoral and cellular components of the patient's immune system. The immunogenic agents find use both in vivo and in vitro.
摘要翻译： 描述了新颖的组合物和方法，用于刺激患者的免疫系统到具有gp72肿瘤相关抗原的肿瘤细胞，从而引起杀肿瘤作用。 提供抗独特型人单克隆抗体和其特异性区域与一级抗体结合选择性地与gp72的抗原决定簇结合，以介导患者免疫系统的体液和细胞成分。 免疫原性试剂在体内和体外均有发现。
-
10.发明授权Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responses 有权编码抗体或其部分的核酸包含异源T细胞表位及其在调节T细胞应答中的用途公开(公告)号：US08742088B2
公开(公告)日：2014-06-03
申请号：US12566465
申请日：2009-09-24
CPC分类号： C07H21/04 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/292 , A61K39/385 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/6056 , A61K2039/70 , C07K16/00 , C07K19/00 , C07K2318/10 , C07K2319/00 , C12N2730/10134 , C12N2760/16134
摘要： The present invention provides a nucleic acid which comprises a non-specific promoter and at least one sequence that encodes a polypeptide that has at least one heterologous T cell epitope therein but does not have any regulatory T cell epitopes. The polypeptide may be one chain of a heterodimer such as the heavy or light chain of an antibody molecule, the heterologous T cell epitope causing disruption of the heterodimer chain such that it cannot bind with the other chain of the heterodimer. The nucleic acid can be used to raise a T cell response against the at least one heterologous T cell epitope.
摘要翻译： 本发明提供了一种核酸，其包含非特异性启动子和编码多肽的至少一个序列，所述多肽在其中具有至少一个异源T细胞表位但不具有任何调节性T细胞表位。 多肽可以是异源二聚体的一条链，例如抗体分子的重链或轻链，异源T细胞表位导致异源二聚体链的破坏，使得其不能与异源二聚体的其它链结合。 所述核酸可用于提高针对所述至少一种异源T细胞表位的T细胞应答。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.024 秒)
